BR100 Increased By (1.02%)
BR30 Increased By (1.71%)
KSE100 Increased By (0.58%)
KSE30 Increased By (0.65%)
BECO 6.03 Increased By ▲ 0.26 (4.51%)
BML 52.61 Decreased By ▼ -0.39 (-0.74%)
BOP 34.23 Increased By ▲ 0.24 (0.71%)
CNERGY 8.16 Increased By ▲ 0.05 (0.62%)
DCL 12.23 Increased By ▲ 0.03 (0.25%)
FCCL 53.80 Increased By ▲ 0.97 (1.84%)
FCSC 5.24 Increased By ▲ 0.17 (3.35%)
FFL 18.03 Increased By ▲ 0.08 (0.45%)
FNEL 1.30 Increased By ▲ 0.01 (0.78%)
HUMNL 11.00 Increased By ▲ 0.12 (1.1%)
KEL 8.07 Increased By ▲ 0.05 (0.62%)
KOSM 5.39 Decreased By ▼ -0.13 (-2.36%)
MLCF 87.90 Increased By ▲ 1.39 (1.61%)
NBP 186.60 Increased By ▲ 1.44 (0.78%)
PACE 10.75 Increased By ▲ 0.17 (1.61%)
PAEL 39.95 Increased By ▲ 0.53 (1.34%)
PIAHCLA 26.19 Decreased By ▼ -0.03 (-0.11%)
PIBTL 17.32 Increased By ▲ 0.65 (3.9%)
PPL 233.49 Increased By ▲ 5.31 (2.33%)
PRL 34.98 Increased By ▲ 0.30 (0.87%)
PTC 67.71 Increased By ▲ 2.38 (3.64%)
SEARL 90.90 Increased By ▲ 0.77 (0.85%)
SSGC 27.20 Increased By ▲ 0.60 (2.26%)
TELE 8.57 Increased By ▲ 0.29 (3.5%)
THCCL 60.85 Increased By ▲ 2.35 (4.02%)
TPLP 8.78 Increased By ▲ 0.56 (6.81%)
TREET 24.65 Increased By ▲ 0.12 (0.49%)
TRG 71.50 Increased By ▲ 1.79 (2.57%)
WAVES 10.01 Increased By ▲ 0.07 (0.7%)
WTL 1.27 Decreased By ▼ -0.01 (-0.78%)
By

COPENHAGEN: The Danish Health Agency said on Friday that it was continuing to offer Moderna's COVID-19 vaccine to under-18s, and that a statement on Wednesday suggesting a suspension had in fact been a miscommunication.

"The Danish recommendations have not been changed," the agency said.

"The Danish Health Agency continues to assess that both COVID-19 vaccines, both the one from Pfizer/BioNTech and the one from Moderna, are highly effective vaccines that have an important place in the general vaccination programme in Denmark."

On Wednesday, Sweden said it would pause using Moderna's shot for people born in 1991 or later as data pointed to an increase of myocarditis and pericarditis among young people who had been vaccinated.

The Danish health agency then said that, while the Pfizer/BioNTech vaccine was anyway its main option for people aged 12-17 years, it had decided to pause administering the Moderna vaccine to under-18s under the "precautionary principle".

It later retracted the statement - although Finland also announced a pause.

"We've communicated badly in this case," the agency's head of press, Tina Gustavsen, told Reuters. "It was simply bad wording."

"We felt there was a need to say that we were not worried. We think it is a good and effective vaccine and we will continue to use it in the Danish programme."

The agency said around 1,200 under-18s had so far received Moderna's shot in Denmark.

Comments

Comments are closed for this article.